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No matter how one deﬁnes standard of care, sentinel
lymph node biopsy (SLNB) has become standard of care
for the treatment of clinically localized melanoma.
1,2
Given this fact, it is surprising that more attention has not
been paid to the issue of false-negative results of sentinel
node biopsy. In the current issue of Annals of Surgical
Oncology, Scoggins et al. report on the false-negative rate
of sentinel node biopsy from a large series of patients
entered prospectively into the multi-institutional Sunbelt
Melanoma Trial.
3 An important starting point for any dis-
cussion of this topic is how to deﬁne and report the false-
negative rate. Some investigators have reported the number
of false-negative sentinel node biopsies (generally deﬁned
as any ﬁrst recurrence of melanoma in a lymph node
potentially draining the primary tumor) occurring out of all
procedures performed. This is an incorrect representation
of the false-negative rate and not a relevant number to
patients and surgeons. In contrast, a very important number
is the ratio of true-negative biopsies to all negative biopsies
(false negatives plus true negatives). This is the negative
predictive value of the sentinel node biopsy procedure and
is of great value to surgeons when they counsel patients
after a negative sentinel node biopsy procedure, but it is
still not the false-negative rate. The negative predictive
value of sentinel node biopsy in large series has been
reported between 94 and 98.5% (Table 1), meaning that
only 2–6 patients per 100 who are told their nodes are
negative are given that information incorrectly. However,
the actual deﬁnition of the false-negative rate is the ratio of
false-negative results to the total number of positive lymph
nodes (false negatives plus true positives). This value has
been reported in the range 6–21%. Importantly, any
method of reporting on the likelihood that a truly positive
lymph node will be missed by the sentinel node procedure
depends on the a priori likelihood that any lymph nodes are
actually involved by melanoma. Put another way, if all the
lymph nodes in a patient are uninvolved by tumor, it does
not matter which nodes the surgeon removes—the result
will be a true negative. The corollary of this, however, is
that patients whose melanoma is most likely to have spread
to the regional nodes are those most likely to have a false-
negative sentinel node biopsy. It also follows that different
series of patients undergoing sentinel node biopsy using
identical techniques (and with identical accuracy) will
report different false-negative rates and negative predictive
values if the baseline characteristics of the melanoma
patients differ. In addition, because nodal recurrences can
take many years to manifest clinically, as the duration of
follow-up increases, the false-negative rate and total posi-
tive node percentage will increase. In the Sunbelt
Melanoma Trial data reported by Scoggins et al., after
median follow-up of 61 months, the overall likelihood of a
positive lymph node was 19.8% (486/2,451), the negative
predictive value of a sentinel node biopsy was 97.0%
(1,906/59 ? 1,906), and the false-negative rate was 10.8%
(59/59 ? 486).
3 The corresponding values in other con-
temporary large series of melanoma patients undergoing
sentinel node biopsy are shown in Table 1.
So now let us ask the question: who is to blame for a
false-negative sentinel node biopsy? Please note that, in this
politically correct (and highly litigious) world, the word
‘‘blame’’ carries connotations that many surgeons would
just as soon avoid. We use the word advisedly (and tongue-
in-cheek) in this editorial: in fact, we do not imply directly
or indirectly that blame should truly be assigned each time a
lymph node recurrence occurs after a prior sentinel node
biopsy, nor do we suggest that anyone did anything wrong
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reason why the sentinel node was reported as negative but
the patient developed a nodal recurrence. So, offered in this
spirit as looking for someone to blame, what are some
possible reasons and what can we learn from them?
Certainly, we must start our discourse by looking to the
surgeon. Are we removing all the correct node(s) each and
every time we perform a sentinel node? Why would we
not? Well, for starters, the operational deﬁnition of a sen-
tinel node is itself somewhat arbitrary, particularly in terms
of the amount of radioactivity that can be contained within
a lymph node before it is deemed hot enough to remove.
Just as arbitrary, if not more so, is the point at which a
basin can be considered clear of residual sentinel nodes,
that is, that any residual radioactivity in the basin repre-
sents background or shine-through from the primary tumor
site. Because of the potential for shine-through to mask a
small retained sentinel node, we might well expect higher
rates of false-negative results the closer the primary tumor
is to the sentinel node, but with the possible exception of
upper outer quadrant breast cancer primaries, this has never
been documented or even directly studied.
4
However, the sentinel node biopsy procedure begins in
Nuclear Medicine, so what can we learn by looking there?
The nuclear medicine technologist has to make sure that
the injection is performed correctly with the Tc
99 sulfur
colloid injection as close to the scar or biopsy site as
possible and in such a way that drainage from that site truly
recapitulates the actual dermal lymphatic drainage of that
particular area of skin. Deeper injection may reduce the
accuracy of identifying true sentinel nodes, as would
injection farther away from the biopsy site. A sobering
study involved patients undergoing lymphoscintigraphy at
the same site on two separate occasions: the same nodes
were not always identiﬁed on both studies, suggesting that
minor technical variations could result in some sentinel
nodes being missed.
5 Even if the correct node accumulates
the radiotracer, ascertaining the location of that node (or
even the basin in which it resides) may be inaccurate,
especially in the head and neck. Certainly, there are
numerous reports to suggest that higher false-negative rates
are associated with head and neck primary sites.
6 A
potential solution could be the use of single-photon emis-
sion computed tomography with computed tomography
scanning (SPECT/CT) lymphoscintigraphy imaging, which
has been shown to increase the resolution and improve
anatomic localization for sentinel nodes in the head and
neck. Van der Ploeg and colleagues showed the potential
value of SPECT/CT lymphoscintigraphy: in a series of 85
patients who underwent both conventional lymphoscintig-
raphy and SPECT/CT imaging prior to SLNB, SPECT/CT
resulted in a different incision in 17 patients, an incision at
another site in 8, and an extra incision in 5 patients.
7
SPECT/CT identiﬁed 12 nodes not seen on standard
scanning (an extra 8%). Ten of these 12 nodes were har-
vested and 2 contained lymphatic metastases. This
certainly provides strong evidence that better lymphoscin-
tigraphy could lower the false-negative rate, especially for
our most difﬁcult sites such as the head and neck.
Can the pathologist be to blame for false-negative
results in certain cases where the correct node has been
identiﬁed and removed? Routine examination of the sen-
tinel node includes immunohistochemical staining
techniques using antibodies to melanocyte lineage anti-
gens, which while very sensitive, is certainly not foolproof.
Even with the intensive attention that the sentinel node
receives, only a small portion of the entire lymph node is
examined. Hence it is entirely possible that the pathologist
may not see the tumor cells in a sentinel node and call it
negative. Those patients would not undergo completion
node dissection and hence would be at risk of failure in
nonsentinel nodes, and these cases would be considered
false-negative results. Evidence suggests that more inten-
sive sampling of the sentinel node does indeed identify
more positive nodes, but as yet there is no proof that this
more time-consuming approach decreases false-negative
results.
8 As we perform sentinel node biopsies for thinner
melanomas (our routine is to recommend the procedure for
TABLE 1 Nodal recurrences after negative sentinel lymph node biopsy for melanoma in selected large series
Author (year
of publication)
Number
of patients
Median
follow-up
(months)
Sentinel node
positivity rate,
TP/all cases (%)
Nodal recurrences
in sentinel node-negative
basin (% of all patients)
Negative
predictive
value (%)
False-negative
rate, FN/
(TP ? FN) (%)
Chao (2002)
15 1183 16 233/1183 (19.7%) 14 (1.1%) 98.5 5.6
Testori (2009)
16 1313 54 220/1313 (16.9%) 36 (2.7%) 96.3 14.4
Morton (2006)
13 769 60 122/769 (16%) 26 (3.3%) 96.0 17.6
Nowecki (2006)
17 1207 36 228/1207 (18.9%) 43 (3.6%) 94.2 20.0
Cascinelli (2006)
18 1108 61 176/1108 (15.9%) 47 (4.2%) 95.0 21.0
FN false negative, TP true positive
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small tumor deposits or even isolated tumor cells being the
only metastases present in the node increases, and the
challenges for the pathologist increase accordingly. In a
paper by Scheri and colleagues examining the impact of
micrometastases (B0.2 mm) and isolated tumor cells in the
sentinel node, the authors found that the incidence of
positive nonsentinel nodes in the completion node dissec-
tion specimen was 12%.
9 In addition, the 5-year
melanoma-speciﬁc survival rate for those patients with
isolated tumor cells or very small metastatic foci when
compared with those who were deemed sentinel node
negative was signiﬁcantly lower (94 vs. 89%, p = 0.02).
Future studies on more intensive analysis of sentinel nodes,
including molecular analysis using reverse-transcriptase
polymerase chain reaction (RT-PCR) technology, should
look at whether these techniques can decrease the false-
negative sentinel node biopsy rate while also taking into
account the potential risk that some of these techniques,
especially RT-PCR, may be identifying false-positive
cases.
10
One potential issue that has only received limited
attention is the potential that the initial melanoma biopsy
could sufﬁciently disrupt lymphatic drainage to result in
false-negative results (meaning we could blame dermatol-
ogists and primary-care practitioners for failures).
Melanomas are diagnosed by biopsies that range from
punch and incisional biopsies that leave much of the lesion
intact to the more common shave, scallop, and excisional
biopsies that remove all grossly evident lesion. Is there any
evidence that, after a biopsy that removes the entire lesion,
the draining lymphatics are sufﬁciently disrupted that the
accuracy of the sentinel node biopsy procedure could be
compromised? Taken to the extreme, Kelemen et al.
demonstrated that, while sentinel node biopsy is feasible
after a previous wide excision, the false-negative rate does
in fact go up.
11 However, to attempt to address the biopsy
issue, Triﬁro et al. identiﬁed 31 patients with lesions that
were clinically considered to represent deﬁnite melanomas
prior to any type of biopsy, and had them undergo lym-
phoscintigraphy before and after excisional biopsy. In 23 of
31 cases the scans were concordant, and in 6 cases new
basins were seen after excisional biopsy was performed.
However, in two cases, nodal basins initially identiﬁed as
draining the primary site were not seen on the postexcision
scan.
12 Although there were no false-negative cases
reported by those authors, their data provide evidence that
clinically appropriate and necessary biopsies may at times
disrupt lymphatic channels sufﬁciently to inﬂuence the
accuracy of sentinel node biopsy, and further studies are
warranted to identify which, if any, primary melanomas
should best be diagnosed by nonexcisional biopsy proce-
dures to minimize this effect.
Lastly, it may not always be any physician’s fault. There
could be immutable patient-related factors that lead to
some irreducible minimum number of false-negative sen-
tinel node biopsies, no matter how well every other aspect
of the patient’s care has proceeded. For example, it may be
that, at time of diagnosis and sentinel node biopsy, there
are already metastatic tumor cells within the lymphatic
channels that simply have not made it all the way to the
node yet. There is no actual evidence for or against this,
and indeed the MSLT-1 randomized trial did not ﬁnd any
evidence that sentinel node biopsy increased the likelihood
of in-transit metastasis.
13 However, we do have evidence of
declining lymphatic dysfunction with age, which may be a
potential factor in some false-negative sentinel node
biopsies. Conway et al. have shown that lymphatic func-
tion, as assessed by radiocolloid transit to and uptake
within the sentinel node, declines with age.
14 This putative
age-related lymphatic dysfunction could be due to limita-
tions of transit of lymph from the primary site to the node,
or it could be due to diminished ﬁltration function of the
aging lymph node, with greater pass-through to second-
echelon nodes. Either of these, but particularly the latter,
could increase false-negative sentinel node biopsy rates in
older patients. Intriguingly, Scoggins et al. found that older
patients were more likely to have false-negative results
than were younger patients.
3
So if false-negative sentinel node biopsy results are
likely to be with us for a while, even if we do everything
right, what are the consequences for our patients? Are they
worse off having a false-negative sentinel node biopsy than
if they had not undergone the procedure at all? The MSLT-
1 randomized trial allowed for a comparison between
patients with a false-negative biopsy, with a 68.4% relapse
rate at 3 years, and those in the observation group who
relapsed in the nodes without a prior sentinel node biopsy
(64.9% at 3 years, p = 0.60).
13 In the Sunbelt Melanoma
Trial results reported in this issue, which did not have a
nodal observation arm, the overall survival of patients with
false-negative sentinel node biopsy results was not statis-
tically signiﬁcantly worse than those with true-positive
sentinel nodes.
3
This is encouraging news that should reassure that small
percentage of patients who do return with a palpable node
months or years after a negative sentinel node biopsy.
However, is there anything we can or should be doing to
detect recurrences earlier in patients at highest risk? First,
who are these patients? Certainly, patients with thick,
ulcerated, and/or high-mitotic-rate primaries are at high
risk for false-negative results, because they are at high risk
of having a positive node in the ﬁrst place. Furthermore, it
seems that older patients, patients with head and neck
primaries, and patients undergoing sentinel node biopsy
after prior wide excision are groups at increased risk of
672 V. K. Sondak, J. S. Zagerfalse-negative biopsy. Perhaps we can even include
patients with discordant results between their lympho-
scintigraphy and the ﬁndings at sentinel node biopsy (e.g.,
those in whom the scan shows three nodes but the sentinel
node procedure only yields two) in this group, although
that is speculative at this point. So what, if anything, should
we do to monitor high-risk patients? The MSLT-2 trial is
prospectively evaluating whether nodal ultrasound can help
monitor nodal basins that are known to be sentinel node
positive but that do not undergo complete dissection. If so,
nodal ultrasound for surveillance of patients considered at
risk of false-negative sentinel node biopsy results would
potentially make sense. Some European centers with
familiarity with ultrasonography already do this, and as we
have become more comfortable with nodal ultrasound at
our institution, we are employing it selectively in our high-
risk sentinel-node-negative patients. However, prospective
evaluation is warranted before this approach is widely
adopted.
So where does this leave us? Nodal recurrences after
prior negative sentinel node biopsy now account for a
signiﬁcant percentage of all clinical stage III melanoma
patients seen in multidisciplinary clinics such as our own.
Improving the accuracy of sentinel node biopsy should be
an active area of research, and efforts to identify and
monitor patients at risk of nodal recurrence after negative
biopsy seem warranted as well. It is time that this important
issue received the attention it deserves.
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